Nootropics Powder Nsi-189 Nsi 189 for Antidepressant drug CAS 1270138-41-4 from buzai232's blog

Nootropics Powder Nsi-189 Nsi 189 for Antidepressant drug CAS 1270138-41-4



NSI189 powder is an experimental antidepressant. Neuralstem, Inc. is currently testing it for use in major depression, in addition to treating cognitive impairments, and brain degeneration. It may induce specific brain regeneration.
NSI-189 is most likely selective only to two nervous system controlling regions in the brain (hippocampus, subventricular zone)
Usage:
1) May Improve Depression
NSI-189 showed promise treating depression and cognitive impairment in a study (double-blind randomized controlled trial) consisting of 24 people split into these three groups :

40 mg once a day or placebo
80 mg (40 mg twice a day) or placebo
120 mg (40 mg three times a day) or placebo
The NSI-189 group had significant improvements in depression symptoms compared to the control group starting from day 28 up to the follow-up (day 84). However, clinical significance was only shown in self-rating scales .

Download our FREE eCourse on BioHacking Your Stress and Anxiety

2) May Benefit Stroke Patients
Since it can increase nerve cell formation (neurogenesis), NSI-189 shows promise as a potential therapy for those that experienced a stroke to improve brain structure and function .

Scientists gave rats NSI-189 6 hours after an induced stroke. NSI treatment that continued for 12 weeks post-stroke resulted in significant improvements in brain and motor deficits. This improvement lasted 24-weeks post-therapy .

NSI also helped remodel rat's brains post-stroke and showed an overall improvement in the initial six months .

3) May Improve Cognitive Function
In a study of 24 depression patients (double-blind randomized controlled trial), NSI-189 increased self-reported cognitive function .

More studies need to be done to determine if this was due to the reduction of depression symptoms, or a result of overall neurogenesis .

4) May Help Increase Neuron Formation
The hypothesized mechanism for NSI-189 was neurogenesis mainly in the hippocampus .

At day 28, NSI-189 showed a non-significant growth in the hippocampus and amygdala when compared to placebo .

Post-study, the left side of the hippocampus showed a moderate increase (but not statistically significant). There were similar effects on the right side of the amygdala .